Microvascular decompression

W. Jeffrey Elias, Kim Burchiel

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Microvascular decompression (MVD) remains the only treatment of trigeminal neuralgia that directly addresses the presumed pathogenesis. It is a proven therapy, associated with the longest duration of pain relief while preserving facial sensation. The authors' premise for advocating early MVD is the belief that the disease's natural progression, in the absence of treatment, is toward the development of more atypical features that are refractory to treatment, signifying ongoing neuropathic injury. In an effort to more successfully select candidates for MVD, the authors have incorporated high-resolution magnetic resonance imaging into our preoperative algorithm, since it has proven extremely accurate in defining the neurovascular relations at the trigminal nerve complex. Microvascular decompression can only be recommended when it is performed with low rates of morbidity.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalClinical Journal of Pain
Volume18
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Microvascular Decompression Surgery
Trigeminal Neuralgia
Therapeutics
Disease Progression
Magnetic Resonance Imaging
Morbidity
Pain
Wounds and Injuries

Keywords

  • Microvascular decompression
  • Surgery
  • Trigeminal neuralgia

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Microvascular decompression. / Elias, W. Jeffrey; Burchiel, Kim.

In: Clinical Journal of Pain, Vol. 18, No. 1, 2002, p. 35-41.

Research output: Contribution to journalArticle

Elias, W. Jeffrey ; Burchiel, Kim. / Microvascular decompression. In: Clinical Journal of Pain. 2002 ; Vol. 18, No. 1. pp. 35-41.
@article{fd74839669e04080b8e06c4034105849,
title = "Microvascular decompression",
abstract = "Microvascular decompression (MVD) remains the only treatment of trigeminal neuralgia that directly addresses the presumed pathogenesis. It is a proven therapy, associated with the longest duration of pain relief while preserving facial sensation. The authors' premise for advocating early MVD is the belief that the disease's natural progression, in the absence of treatment, is toward the development of more atypical features that are refractory to treatment, signifying ongoing neuropathic injury. In an effort to more successfully select candidates for MVD, the authors have incorporated high-resolution magnetic resonance imaging into our preoperative algorithm, since it has proven extremely accurate in defining the neurovascular relations at the trigminal nerve complex. Microvascular decompression can only be recommended when it is performed with low rates of morbidity.",
keywords = "Microvascular decompression, Surgery, Trigeminal neuralgia",
author = "Elias, {W. Jeffrey} and Kim Burchiel",
year = "2002",
doi = "10.1097/00002508-200201000-00006",
language = "English (US)",
volume = "18",
pages = "35--41",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Microvascular decompression

AU - Elias, W. Jeffrey

AU - Burchiel, Kim

PY - 2002

Y1 - 2002

N2 - Microvascular decompression (MVD) remains the only treatment of trigeminal neuralgia that directly addresses the presumed pathogenesis. It is a proven therapy, associated with the longest duration of pain relief while preserving facial sensation. The authors' premise for advocating early MVD is the belief that the disease's natural progression, in the absence of treatment, is toward the development of more atypical features that are refractory to treatment, signifying ongoing neuropathic injury. In an effort to more successfully select candidates for MVD, the authors have incorporated high-resolution magnetic resonance imaging into our preoperative algorithm, since it has proven extremely accurate in defining the neurovascular relations at the trigminal nerve complex. Microvascular decompression can only be recommended when it is performed with low rates of morbidity.

AB - Microvascular decompression (MVD) remains the only treatment of trigeminal neuralgia that directly addresses the presumed pathogenesis. It is a proven therapy, associated with the longest duration of pain relief while preserving facial sensation. The authors' premise for advocating early MVD is the belief that the disease's natural progression, in the absence of treatment, is toward the development of more atypical features that are refractory to treatment, signifying ongoing neuropathic injury. In an effort to more successfully select candidates for MVD, the authors have incorporated high-resolution magnetic resonance imaging into our preoperative algorithm, since it has proven extremely accurate in defining the neurovascular relations at the trigminal nerve complex. Microvascular decompression can only be recommended when it is performed with low rates of morbidity.

KW - Microvascular decompression

KW - Surgery

KW - Trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=0036161421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036161421&partnerID=8YFLogxK

U2 - 10.1097/00002508-200201000-00006

DO - 10.1097/00002508-200201000-00006

M3 - Article

VL - 18

SP - 35

EP - 41

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 1

ER -